Telomerase as a target in diagnosis and treatment of cancer in postmenopausal women

Znaczenie telomerazy w diagnostyce i terapii onkologicznej u kobiet po menopauzie

Natalia Lipińska, Błażej Rubiś

Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, Poznan; Head of Department: Prof. Maria Rybczyńska

Przegląd Menopauzalny 2013; 6: 478-483

Summary

Telomeres and telomerase are responsible for protection and maintenance of genomic stability of all eukaryotic cells. Several studies showed that one of the most distinguishing features of cancer cells is an increased expression and activity of telomerase, in contrast to somatic cells. This gives an opportunity for use of telomerase as a specific marker of cancer lesions or even as a molecular target. However, there are some questions concerning diagnostic specificity of this marker especially in the context of high proliferation potential of normal cells, such as the uterus and ovaries. The proliferation potential, however, decreases due to the menopause syndrome. Women’s age and hormonal changes influence the functioning of many tissues, including alterations in telomerase activity of endometrial and ovarian cancer cells. The different characteristics of telomerase activity and telomere length in cells of postmenopausal women give an opportunity to utilize the telomeres and telomerase for the development of new cancer diagnostic tests and therapeutic methods. This work is aimed to summarize the information about the significance of telomeres and telomerase in the diagnosis and treatment of cancer in postmenopausal women.

Key words: telomerase, telomeres, ovarian cancer, endometrium, post-menopausal women.

Introduction

Cancers are characterized by uncontrolled and unlimited ability to proliferate and metastasize. Many years of research led to the discovery of a number of tumor markers but only few of them reveal proper tissue specificity and diagnostic sensitivity, allowing their use in diagnosis of cancer. In 1984, when telomerase was discovered, new hopes for its use as a universal...
marker of malignant transformation appeared. Human somatic cells are characterized by a limited ability to proliferate, which is a result, among others, of a low level of telomerase expression and activity in these cells. On the other hand, most cancer cells express telomerase and thus maintain high proliferative potential [1]. Changes that occur in the post-menopausal women are complex and multifactorial but, paradoxically, give an opportunity to develop new diagnostic tests and novel methods of cancer treatment, including therapeutic schemes based on the detection of telomerase activity and telomere length. This seems to be of great interest and importance especially since research studies show that approximately 85-90% of the 3000 kinds of cancers are characterized by high telomerase activity [2].

Telomeres and telomerase

Telomeres are constitutive elements of eukaryotic chromosomes. They are located at the 3' ends of DNA strands, composed of guanine-rich repeated sequences: 5'-TTAGGG-3', and stabilized by telomere binding proteins (TBP) as well as shelterin complex [3, 4]. The primary role of telomeres is to protect and maintain the stability of the genome. Further, the specific telomere structures with D-loop and T-loop at the end of chromosome prevent them from nonhomologous end joining (NHEJ) and degradation by exonucleases [5]. Telomeres shorten by 50-200 nucleotides with each cell division as a result of the inability of DNA polymerase to complete replication of the lagging strand (“end replication problem”). Telomere length in human somatic cells ranges from 3 to 12 kb [6] and it limits the maximum number of cell divisions (Hayflick limit) to several dozen in vitro [7]. Telomere shortening to a critical length results in the loss of telomere protection, which leads to chromosomes instability, stops cell division and replicative senescence may be initiated [8]. Some cells, however, exhibit unlimited capacity for proliferation through the telomerase complex activity. Human telomerase is a multisubunit ribonucleoprotein that belongs to the reverse transcriptases (RT) family and is responsible for de novo addition of TTAGGG repeats onto chromosome ends. Two essential components are necessary for the functioning of telomerase in vitro: telomerase reverse transcriptase catalytic subunit (TERT) and a functional telomerase RNA (TR, TERC) that serves as a template for telomere extension. In addition, the telomerase complex (in vivo) consists of telomerase-associated proteins such as dyskerin (DKC1), NOP10, NHP2, GAR1. It is also stabilized by the shelterin complex proteins with various functions in enzyme biogenesis, localization, and regulation [4, 9]. Some cell lines have been reported to use a telomerase-independent mechanism to maintain the telomere length, known as alternative lengthening of telomeres (ALT), which involves the use of a DNA template and homologous recombination-mediated mechanism of telomere elongation [10]. Thus, there are at least two mechanisms that provide cancer cells to prevent telomeres shortening and to avoid apoptosis.

Telomerase expression and activity

Production of an active telomerase complex is possible by two major genes expression: TERT – coding for reverse transcriptase and TERC – coding for RNA template. While TERC is constitutively expressed in all cells, the TERT is not. This gene is considered to be a crucial one for the functioning of the enzyme, since the increased telomerase activity mostly correlates with an increased TERT mRNA [9]. Telomerase activity is closely linked to the proliferative potential of cells. Hence, cells at the blastocyst stage and most of the embryonic cells before the 20th week of fetal development reveal high telomerase activity. After birth, telomerase activity is gradually reduced in most somatic cells, with the exception of intensively dividing and self-renewing cells. Elevated activity of telomerase is observed in bone marrow, skin, endometrium, gastrointestinal tract, testis and stem cells [11]. In the peripheral blood, the highest telomerase expression is observed in thymocytes and circulating activated T cells [12]. Along with shortening of the telomere length in peripheral blood cells, the level of telomerase activity in leukocytes decreases with age, until it becomes undetectable in humans about 40 s [13]. However, the profile of telomerase activity also depends on changes occurring in the body, particularly in the female body during menopause. A decrease in estrogen and progesterone levels leads to changes in cell proliferative capacity in the reproductive system, and changes in the level of those hormones has been linked to changes in telomerase activity in these cells [14].

Telomerase and cancer

In postmenopausal women an increasing incidence of certain types of cancer is observed. About the age of 50, the risk of breast, ovarian, endometrial, lung and colon cancer increases [15, 16]. Both hormonal fluctuations and age are major risk factors for these cancers [16]. In addition, hormone replacement therapy (HRT) results in longer exposure to estrogens and can predispose to the development of these cancers [17]. Many years of research have revealed that telomerase is specifically activated in most malignant tumors. From the diagnostic perspective it is crucial to identify at which stage of carcinogenesis the activity of the enzyme increases. In some cancers, telomerase expression increases gradually with tumor progression, while in others it is observed even in the in situ stage [18-20]. About 90% of invasive breast cancers and 75-90% of ductal carcinomas in situ exhibit
the TERT expression or telomerase activity [19]. Furthermore, a correlation was observed between the increase in the average telomerase activity and tumor progression in 14% of benign lesions, and in 92% and 94% of ductal and invasive carcinoma, respectively [21]. A similar correlation has been demonstrated for lung cancer. In 62-94% of non-small cell lung cancer (NSCLC), and in almost 100% of small cell lung cancer (SCLC), telomerase activity is detected and its level correlates with the histological type, severity and survival [20]. For other cancers, telomerase activity values are more diverse, the percentage of telomerase positive bone cancer is 11-58%, for liposarcoma 26-86% and 56-90% for renal carcinoma [19, 22, 23]. Noteworthy, skin and colon are also proliferative tissues that display a reduction in proliferative capacity with an increasing age [11, 15, 16]. The studies revealed that these changes are also reflected in telomerase activity as well as telomere length alterations.

As shown in the vast majority of cases, identification of telomerase activity can distinguish cancer from normal tissue, and in some cases and cancer types, the enzyme activity correlates with the tumor stage (Table I).

### Table I. Telomerase activity in selected normal and cancer tissues

<table>
<thead>
<tr>
<th>Tissue/Organ</th>
<th>Telomerase positive (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal tissue</td>
</tr>
<tr>
<td>endometrium</td>
<td>11-89</td>
</tr>
<tr>
<td></td>
<td>89</td>
</tr>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td>cervix</td>
<td>0-19</td>
</tr>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>n.d.</td>
</tr>
<tr>
<td>ovary</td>
<td>0-33</td>
</tr>
<tr>
<td></td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>n.d.</td>
</tr>
<tr>
<td>breast</td>
<td>0-4</td>
</tr>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td>lung</td>
<td>0-4</td>
</tr>
<tr>
<td></td>
<td>4</td>
</tr>
<tr>
<td>bladder</td>
<td>0-29</td>
</tr>
<tr>
<td></td>
<td>n.d.</td>
</tr>
<tr>
<td>kidney</td>
<td>0-75</td>
</tr>
</tbody>
</table>

n.d. – no data in references

Normal endometrial cells in premenopausal women, in contrast to most somatic cells of the organism, reveal telomerase activity, and their level varies depending on the phase of the cycle. Włażlak et al. showed that 85% of endometrial cells in the proliferative phase and 45% of cells in the secretory phase show telomerase expression [31]. Atrophic endometrium in postmenopausal women loses the ability to proliferate intensively. Moreover, telomerase expression in atrophic cells is significantly lower than in the cells of a proliferative stage and endometrial cancer cells [32, 33]. It was suggested that it might give an opportunity to use the measurement of the expression of telomerase as a marker for distinguishing malignant and normal endometrial cells in postmenopausal women [33, 34].

The tissues exhibiting constitutive telomerase activity include also the ovaries. Expression of the enzyme is particularly high in young ovaries and decreases with age. Kinugawa et al. suggested that the depletion of follicles activity is directly related to the decrease in the telomerase level, which makes the assessment of functional ovarian age possible by measuring telomerase activity.
Ageing oocytes, due to low telomerase activity, are unable to prevent damage of chromosomes that leads to fertility decline [35]. Like other cancers, about 90-97% of ovarian tumors show an up-regulation of telomerase activity. A positive correlation was also observed in cases of lymph node metastasis. Despite the telomerase activity in normal ovarian tissue, telomerase can be still perceived as a potential marker in ovarian cancer since in normal tissue, telomerase activity is derived only from the germ line cells that display lower telomerase activity than observed in cancer cells [36].

The leading technique to assess telomerase activity is telomeric repeat amplification protocol (TRAP assay). It engages the polymerase chain reaction (PCR) method and analysis of products of telomerase action, i.e. elongation of primers mimicking telomeres sequence. The detection system is based on qPCR or ELISA assay and, when compared to standards, enables a quantitative measurement [37]. The TRAP assay detects telomerase activity with high sensitivity, even in a single cell. PCR step of the TRAP assay is a source of potential problems, hence several non-PCR methods are also used. One of the most promising alternative methods is isothermic transcription-mediated amplification (TMA) also combined with detection based on hybridization-protection assay (HPA) and telomeric repeat elongation (TRE) based on biosensor technology [38]. The sensitivity of telomerase activity assays may be increased by a simultaneous assessment of hTERT expression. Thus, a combination of these two assays might be useful in early identification of the tumor as well as its classification [39].

Telomere length is closely related to the proliferative rate and lifespan of cells. Short telomeres could be a byproduct of the cancer cell’s high proliferative rate but on the other hand, might trigger early carcinogenic events. Some researchers indicate no association of this parameter with the risk of cancer, while others indicate a correlation of both i.e. shorter and longer telomeres, to the increased risk of cancers in postmenopausal women [40, 41]. Wang et al. showed changes in telomere length (shortening or elongation) in 60% of ovarian, 73.9% of endometrial, and 64.3% of cervical cancers [42]. On the contrary, the lack of any clinical significance to telomere length in breast as well as ovarian and endometrial cancers was suggested in some reports [43, 44]. These differences are probably caused by various methods applied and different characteristics of patient groups [41]. Thus, some doubts concerning a direct relation between relative telomere length, mostly measured in peripheral blood cells, and telomere length in cancer cells [45] still remain. However, telomerase activity and TERT expression measurements, complemented by analysis of telomere length and other molecular markers of cancer, have a chance to evolve towards a useful tool in diagnosis and monitoring of the disease. For cancer diagnosis, especially of the reproductive system, it is important to consider whether the patient has already entered a period of menopause.

**Therapeutic target – telomere**

A widespread expression of telomerase in cancer cells, and its lower level in the majority of somatic cells provide a solid basis for the application of specific targeted therapy directed against cancer. Such therapies are focused on inhibiting telomerase activity, forcing cancer cells to stop divisions (by a critical reduction in the telomere length) and redirect them to apoptotic cell death [46]. Control of telomerase is possible at several levels, including the expression of genes encoding telomerase subunits, posttranslational modifications and the phosphorylation of proteins [47]. A lot of methods are focused on the impact on TERT or TR subunits. Chemically synthesized small molecule inhibitors of human telomerase, such as BIBR1532, exhibit a non-competitive inhibitory effect on the telomerase active site of TERT. In preclinical studies on breast cancer (MDA-MB-231) and lung (HTI-H430) cell lines, a significant decrease in telomere length and inhibition of cell proliferation was observed [48]. Other studies showed that an antisense oligonucleotide – GRN163L, blocks the expression of the TR subunit of telomerase [49]. Since positive results of the preclinical studies were obtained, GRN163L has been introduced into clinical trials (imetelstat), to treat both solid and hematological tumors including breast, lung, liver, prostate and other [47, 49]. Moreover, gene therapy utilizes also siRNA, ribozymes, suicide genes and oncolytic virus genes [43].

Due to the fact that telomerase peptides are tumor specific antigens, great expectations are associated with the use of immunotherapy. The most promising vaccines include GV-1001, GRNVAC1 and Vx-001, targeted to redirect the immune system against tumor cells with telomerase expression [50]. BRACO-19 is a G-quadruplex stabilizing substance and has the ability to induce senescence and apoptosis, with high efficacy against cancer with shorter telomere length and inhibition of cell proliferation was observed [48]. Other studies showed that an antisense oligonucleotide – GRN163L, blocks the expression of the TR subunit of telomerase [49]. Since positive results of the preclinical studies were obtained, GRN163L has been introduced into clinical trials (imetelstat), to treat both solid and hematological tumors including breast, lung, liver, prostate and other [47, 49]. Moreover, gene therapy utilizes also siRNA, ribozymes, suicide genes and oncolytic virus genes [43].

We are focused on identification of telomerase inhibiting agents but substances that activate telomerase may constitute another important subject of interest. TA-65 – a telomerase activator isolated from plant Astragalus and Ginkgo biloba extract, may become a crucial compound in degenerative diseases treatment and anti-aging therapy [53]. Despite the strengths of the potential use of telomerase inhibitors, we should not forget about the risk...
Summary and conclusions

Targeting telomerase has been one of the most promising forms of cancer therapy to date, however new substances are still being identified. Their modes of action are based on the presence of telomeres and activity of telomerase. In the age of personalized medicine it is extremely important to adapt therapy to the patient, with a particular reference to the genetic profile of cancer, predisposition of a patient and current physiological condition of the body. Women during and after menopause are a special group of patients. Hormonal changes and their effect on telomerase activity should be taken into consideration when the choice of appropriate oncological treatment is made. Furthermore, changes in telomerase activity that are specific to post-menopausal women, give a potential opportunity of using this factor in early diagnosis of cancer. Numerous researchers still search for new, more specific tumor markers. However, more intensive research is needed in the field of telomerase expression/activity measurement that might become a potential marker of malignancy, reflecting diversity of cancer types, development stage and hormonal profile.

The present review was supported by 2011/03/B/NZ7/00512 research grant.

References


